SPAC

Bullion Consortium Inc. and LIG Assets, (LIGA) Signs LOI to Purchase Construction Companies

Retrieved on: 
Wednesday, November 8, 2023
SPAC, Acquisition, Real estate, Social media, OTC Markets Group, Housing, Negotiation, Green, LIGA, Letter, Retail

Bullion has recently announced they have formed a 506 D Private Placement offering to raise growth operating capital for their initial acquisitions.

Key Points: 
  • Bullion has recently announced they have formed a 506 D Private Placement offering to raise growth operating capital for their initial acquisitions.
  • In addition, Bullion is currently negotiating to acquire a SPAC and several other public companies to merge one of several Real Estate construction and technology companies they are currently contracting to acquire.
  • Insultex will increase comfort in a building structure by reducing drafts and increasing its efficiency.
  • UV inhibitors are blended into the polymeric material to protect it from harmful ultraviolet degradation.

Innovid Reports Q3 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Adjustment, SPAC, Risk, FY, NYSE, Tax, CTV, Public expenditure, EBITDA, Telephone, Intellectual property, GAAP, Free cash flow, Acquisition, Entrepreneurship, Bank statement, Advertising, NBCUniversal, Growth, NBC, Webcast, Bausch Health, Depreciation, Universal, Annual report, Failure, Pharmaceutical industry, Bookkeeping, Cryptocurrency, Self storage, Bank, Innovid

Our Q3 results are evidence of our increased operational efficiency and our focus on profitable growth.

Key Points: 
  • Our Q3 results are evidence of our increased operational efficiency and our focus on profitable growth.
  • Innovid will be hosting an Investor Day detailing the company's vision, market opportunities, and product innovation on November 30, 2023 in New York City.
  • Innovid is providing the following financial guidance for Q4 and full year 2023:
    Q4 2023 revenue in a range between $35 million and $37 million.
  • Innovid also discloses and discusses non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin and Free Cash Flow.

Waldencast’s (WALD) stock sinks after copping to inflating revenues- Hagens Berman

Retrieved on: 
Tuesday, November 7, 2023
Bank statement, Person, SPAC, Sale, Hagens Berman, WALD, FYE, Cosmeceutical, Book, Pharmaceutical industry, Cryptocurrency, Life insurance, Zein E. Obagi

Most recently, on July 5, 2023, Waldencast announced that it would restate financial statements for the year ended December 31, 2021, and for the quarterly periods ended Mar.

Key Points: 
  • Most recently, on July 5, 2023, Waldencast announced that it would restate financial statements for the year ended December 31, 2021, and for the quarterly periods ended Mar.
  • 31, 2022 and June 30, 2022 as a result of improper revenue recognition involving Obagi sales to its Southeast Asia distributor.
  • “We’re focused on investors’ losses and whether Waldencast cooked its books,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

Perception Capital Acquires RCF Acquisition Corp., Announces Plans to Extend and Re-Brand

Retrieved on: 
Tuesday, November 7, 2023
SPAC, Security (finance), RCF, Acquisition, Trust, TM Capital Corp., Perception, Roman Catholic Diocese of La Crosse

Minneapolis, MN, Nov. 07, 2023 (GLOBE NEWSWIRE) -- RCF Acquisition Corp. (the “Company”), announced today the closing of a Securities Purchase Agreement between Perception Capital Partners IV LLC and RCF Sponsor VII LLC, pursuant to which Perception Capital Partners IV LLC will succeed RCF Sponsor VII LLC as the managing sponsor.

Key Points: 
  • Minneapolis, MN, Nov. 07, 2023 (GLOBE NEWSWIRE) -- RCF Acquisition Corp. (the “Company”), announced today the closing of a Securities Purchase Agreement between Perception Capital Partners IV LLC and RCF Sponsor VII LLC, pursuant to which Perception Capital Partners IV LLC will succeed RCF Sponsor VII LLC as the managing sponsor.
  • Perception Capital Partners IV LLC is affiliated with Perception Capital Partners, a private and public investment firm and serial sponsor of special purpose acquisition companies (SPACs).
  • “We are delighted to partner with the RCF team,” said Rick Gaenzle, the Company’s new Chief Executive Officer.
  • Financial Group, LLC (“CCM”), is serving as exclusive financial advisor and lead capital markets advisor to RCF Acquisition Corp.

HLLY SHAREHOLDER ALERT: Johnson Fistel Investigates Holley Inc. f/k/a Empower Ltd.

Retrieved on: 
Tuesday, October 31, 2023
SPAC, LLP, NYSE, SAN, Special-purpose acquisition company

SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Holley Inc. f/k/a Empower Ltd. (NYSE: HLLY), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.

Key Points: 
  • SAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Holley Inc. f/k/a Empower Ltd. (NYSE: HLLY), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.
  • What if I purchased Holley securities?
  • If you purchased Holley securities and suffered significant losses on your investment, join our investigation now:
    There is no cost or obligation to you.
  • On July 16, 2021, Empower Ltd., a SPAC (Special Purpose Acquisition Company), and Holley Intermediate Holdings, Inc. completed a business combination in which the company began trading on the NYSE under the name Holley Inc.

Waldencast’s (WALD) stock sinks after copping to inflating revenues- Hagens Berman

Retrieved on: 
Monday, October 30, 2023
Person, SPAC, Sale, WALD, Cosmeceutical, Bank statement, FYE, Hagens Berman, Book, SAN, Cryptocurrency, Pharmaceutical industry, Life insurance, Zein E. Obagi

SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .
  • Most recently, on July 5, 2023, Waldencast announced that it would restate financial statements for the year ended December 31, 2021, and for the quarterly periods ended Mar.
  • 31, 2022 and June 30, 2022 as a result of improper revenue recognition involving Obagi sales to its Southeast Asia distributor.
  • “We’re focused on investors’ losses and whether Waldencast cooked its books,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Cohen & Company Capital Markets Continues Strong Momentum, Appoints Gary Quin Senior Advisor, EMEA Investment Banking to Expand Global Reach

Retrieved on: 
Monday, October 30, 2023
Credit Suisse, Fairfax Financial, Government, SPAC, Harvard Business School, Capital market, IPO, Sale, Aer Lingus, Vice, Blackstone Inc., Digicel, Investment, Irish government response to the COVID-19 pandemic, Acquisition, University, IA Financial Group, MBA, REIT, Fidelity Investments, Growth, Trinity College, University College Cork, CCM, Pleasure, Commander, U.S. Pacific Fleet, Trinity College Dublin, Senior advisor, NAAC, Financial services, Cryptocurrency, Saudi Aramco

MENLO PARK, Calif. and NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Cohen & Company Capital Markets ("CCM") is pleased to announce the appointment of Gary Quin as Senior Advisor, who will lead CCM's efforts in Europe, the Middle East, and Africa (EMEA).  

Key Points: 
  • Gary brings a wealth of expertise to CCM, including over 25 years of investment banking, operating, and investing experience.
  • Gary previously served as the CEO of North Atlantic Acquisition Corp (NAAC), a Nasdaq-listed SPAC with a primary focus on European acquisition opportunities.
  • Prior to NAAC, he served as Vice Chairman of Credit Suisse's investment banking division in Europe, advising corporations, governments and governmental organizations, financial sponsors and family offices on M&A and capital raising.
  • During his tenure at Credit Suisse, Gary successfully raised $66 billion in both private and public markets.

Holley, Inc. SHAREHOLDER ALERT: Johnson Fistel Encourages Holley Inc. f/k/a Empower Ltd. Shareholders with Losses to Contact the Firm Regarding Investigation

Retrieved on: 
Tuesday, October 24, 2023
SPAC, LLP, NYSE, SAN, Special-purpose acquisition company

The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

Key Points: 
  • The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
  • If you purchased Holley securities and suffered significant losses on your investment, join our investigation now:
    There is no cost or obligation to you.
  • The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors.
  • Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Retrieved on: 
Tuesday, October 24, 2023
TenX, READ, Suite, Food, Medication, Lexington Avenue, Auxiliary routes of Arkansas Highway 18, SPAC, Sale, Form, Acquisition, ONCE, CTCL, Patient, Person, Commerce, PD-1, Newbridge, Non-Hodgkin lymphoma, FDA, Biologics license application, Regulation of tobacco by the U.S. Food and Drug Administration, Prospectus, Peripheral T-cell lymphoma, Annual report, BLA, Security (finance), Pharmaceutical industry, Bank, Cryptocurrency, Citius, Altius, Fortius

CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition (“TenX”) (NASDAQ: TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange. The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”). Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Key Points: 
  • The newly combined public company will be named Citius Oncology, Inc. (“Citius Oncology”).
  • Our majority ownership position and shared services agreement ensures that the Citius Pharma management team will remain fully engaged with the development and commercialization efforts at Citius Oncology.
  • “We are very pleased to announce the proposed merger with Citius Oncology,” said Mr. Xiaofeng Yuan, Chairman and CEO of TenX.
  • In the transaction, all shares of Citius Pharma’s wholly owned subsidiary would be converted into the right to receive common stock of Citius Oncology.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Waldencast plc (WALD) Investors with Substantial Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Monday, October 23, 2023
Person, SPAC, Sale, WALD, Cosmeceutical, Bank statement, FYE, Hagens Berman, Book, SAN, Cryptocurrency, Pharmaceutical industry, Life insurance, Zein E. Obagi

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Waldencast plc (NASDAQ: WALD) investors who suffered substantial losses to submit your losses now .
  • Most recently, on July 5, 2023, Waldencast announced that it would restate financial statements for the year ended December 31, 2021, and for the quarterly periods ended Mar.
  • 31, 2022 and June 30, 2022 as a result of improper revenue recognition involving Obagi sales to its Southeast Asia distributor.
  • “We’re focused on investors’ losses and whether Waldencast cooked its books,” said Reed Kathrein, the Hagens Berman partner leading the investigation.